EyeWorld India March 2015 Issue

March 2015 15 EWAP FEATURE See us at ASCRS ‘15 Booth #2545 LENSTAR LS 900 Improving outcomes. Sophisticated IOL Prediction The on-board Olsen formula, combined with measured lens thickness provides the surgeon with premium IOL power prediction results in all kind of eyes. T-Cone Toric Platform True Placido-Topography of the optional T-Cone complements the LENSTAR’s comprehensive measurement palette. Intuitive graphical planning of the toric intervention based on latest IOL calculation technology by Prof. Barrett is provided to the surgeon in the optional EyeSuite IOL Toric Planner. Automated Positioning System APS Taking biometry measurements has never been easier. LENSTAR APS assists the user with dynamic eyetracking, facilitating measurement acquisition with one click. www.haag-streit.com ADV_Lenstar_APS_ Asia_Pacific_18-02-2015.indd 1 20.02.2015 11:11:04 References 1. Chang DF, Braga-Mele R, Mamalis N, Masket S, Miller KM, Nichamin LD, Packard RB, Packer M. Prophylaxis of postoperative endophthalmitis after cataract surgery; results of the 2007 ASCRS member survey; the ASCRS Cataract Clinical Committee. J Cataract Refract Surg. 2007;33:1801–1805. 2. ESCRS Study Group. Prophylaxis of postoperative endophthalmitis following cataract surgery: Results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33:978–988. 3. American Academy of Ophthalmology Cataract and Anterior Segment Panel. Preferred Practice Pattern Guidelines. Cataract in the Adult Eye. San Francisco, CA: American Academy of Ophthalmology; 2011. Available at www.aao.org/ppp. 4. Packer M, Chang, DF, Dewey SH, Little BC, Mamalis N, Oetting TA, Talley-Rostov A, Yoo SH. Prevention, diagnosis and management of acute postoperative bacterial endophthalmitis. J Cataract Refract Surg. 2011;37:1699–1714. 5. Friling E, Lundström M, Stenevi U, Montan P. Six-year incidence of endophthalmitis after cataract surgery: Swedish national study. J Cataract Refract Surg. 2013;39:15–21. 6. Shorstein NH, Winthrop KL, Herrington LJ. Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department. J Cataract Refract Surg. 2013;39:8–14. 7. Barry P, Cordoves L, Gardner S. ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery. Published by the European Society of Cataract & Refractive Surgeons. 2013. 8. Barry P. Adoption of intracameral antibiotic prophylaxis of endophthalmitis following cataract surgery. Update on the ESCRS Endophthalmitis Study. J Cataract Refract Surg. 2014;40:138–142. 9. Braga-Mele R, Chang DF, Henderson BA, Mamalis N, Talley-Rostov A, Vasavada A. Intracameral antibiotics: Safety, efficacy, and preparation. J Cataract Refract Surg. 2014;40(12):2134-2142. Contact information Chang: dceye@earthlink.net Results - from page 13 Developed collaboratively by Imprimis, ophthalmologists, and pharmacists, TriMoxi and TriMoxiVanc are injected into the vitreous through the zonules using a cannula after placement of the IOL. This technique is superior to intracameral injection, Dr. Liegner said, because intraocular infections take hold in the vitreous, not the anterior chamber. “Inoculation with the infectious bacteria occurs during the procedure most likely from normal resident flora, and becomes deposited into the vitreous as a consequence of fluid irrigation,” he said. “The vitreous, a nutrient-rich protein matrix, not unlike an agar plate, invites rapid and successful growth of the bacteria, somewhat protected from the body’s immune system due to intraocular privilege. Depositing the antibiotic into the vitreous directly attacks any wayward inoculation that might have occurred.” In addition to stopping infection at the source, the drugs also control postoperative inflammation and protect against surgery-induced cystoid macular edema. By combining antibiotics and a steroid into one injection, 95% of patients no longer need postoperative eye drops, Dr. Liegner said. EWAP Editors’ note: Dr. Henderson has financial interests with Alcon. Dr. Liegner has financial interests with Imprimis Pharmaceuticals. Dr. Vasavada has financial interests with Alcon. Contact information Henderson: bahenderson@eyeboston.com Liegner: liegner@embarqmail.com Vasavada: icirc@abhayvasavada.com